poisar

Stocks · News reference

Barclays Maintains Equal-Weight on Anteris Technologies Glb, Lowers Price Target to $9

BenzingaBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncThe Insight Partners

    Transcatheter Aortic Valve Replacement Market to Reach US$ 30.01 Billion by 2035 at 15.2% CAGR, Driven by Improved Clinical Outcomes and Increasing Adoption of Catheter-Based Cardiac Interventions | Exclusive Report by The Insight Partners

    The global Transcatheter Aortic Valve Replacement (TAVR) market is projected to grow from US$ 8.41 billion in 2025 to US$ 30.01 billion by 2035, driven by increasing prevalence of aortic stenosis, aging populations, and rising adoption of minimally invasive cardiac procedures. Technological advancements in valve platforms and delivery systems are creating growth opportunities, with Asia Pacific emerging as the fastest-growing region.

  2. Globenewswire IncNa

    Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026

    Anteris Technologies announced positive 30-day clinical and hemodynamic outcomes for its Medium-size DurAVR Transcatheter Heart Valve in 22 severe aortic stenosis patients. The valve demonstrated single-digit mean gradients, large effective orifice areas, no moderate or severe paravalvular leaks, and zero valve-related mortality. The company is advancing its PARADIGM pivotal trial, a randomized controlled study comparing DurAVR to commercially available TAVR devices in approximately 1,000 patients.